Latest Financial Performance News

Wellnex Life reported a strong 40.4% revenue increase to $23.6 million in FY25, alongside a 57% improvement in normalised EBITDA loss, signaling progress despite ongoing investment costs.

Zicom Group Limited reported a 17% rise in net profit and a significant reduction in debt for FY2025, while adopting a cautious stance on dividends amid ongoing global economic uncertainties.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

5G Networks Limited (5GN) reported a robust 27% revenue increase in FY25, driven by organic growth and a strategic acquisition of an 89.65% stake in cybersecurity firm AUCyber. The company’s underlying EBITDA turned positive, signaling a financial turnaround despite integration costs.

Jcurve Solutions Limited reported a significant turnaround in FY25 with a Normalised EBITDA profit and a narrowed net loss, despite an 11% revenue decline. The company also strengthened its Asia presence through acquisition and boosted liquidity with a $1 million capital raise.

Spenda Limited reported a 106% surge in revenue to $11.1 million for FY25, driven by acquisitions and expanded services, yet posted a substantial $24.3 million net loss largely due to goodwill impairment. The company’s strategic moves and funding needs highlight a pivotal phase ahead.

BPH Global Limited reported a strong 161.7% revenue increase to nearly $288,000 for FY25, driven by new seaweed operations in Indonesia, yet the company remains in the red with a $1.3 million net loss. The firm continues to raise capital and integrate acquisitions as it charts a path forward.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

ClearVue Technologies reported a striking 553% revenue increase to nearly $250,000 in FY2025, alongside a 7% reduction in net loss, driven by strategic partnerships and global project wins.

Codeifai Limited reported a near doubling of its half-year loss to $3.93 million, alongside a 32% revenue drop, while pursuing transformative AI and quantum security acquisitions and securing $2.35 million in fresh capital.

Aumake Limited reported a strong 54% jump in revenue to nearly $40 million for FY25, while cutting its net loss by 45%. The company’s strategic pivot to higher-margin products and key distribution deals set the stage for an ambitious FY26.